Summary of H.R. 3546: Prescription Drug Price Relief Act of 2025

Overview

The Prescription Drug Price Relief Act of 2025 is a bill introduced in the U.S. House of Representatives with the goal of reducing the high cost of prescription drugs for consumers in the United States. The bill proposes several measures aimed at lowering drug prices and increasing affordability and access to essential medications.

Key Provisions

1. Drug Price Negotiation: The bill would require the Secretary of Health and Human Services to directly negotiate with drug manufacturers to set maximum fair prices for certain high-cost prescription drugs covered under Medicare Part D.

2. Price Ceiling: The bill establishes a price ceiling for prescription drugs, limiting the maximum price that can be charged to no more than 120% of the median price charged in a selected set of economically comparable countries (Canada, the United Kingdom, Germany, France, and Japan).

3. Enforcement Mechanisms: The bill includes penalties for drug manufacturers that refuse to comply with the price negotiation and ceiling requirements, including potential exclusion from Medicare and Medicaid programs.

4. Rebates for Excessive Price Increases: The bill would require drug manufacturers to provide rebates to the federal government for any price increases that exceed the rate of inflation.

5. Improved Affordability for Consumers: The savings achieved through the price negotiation and ceiling requirements would be passed on to consumers in the form of reduced out-of-pocket costs for prescription drugs covered under Medicare Part D.

Affected Stakeholders

• Consumers: The bill is intended to make prescription drugs more affordable and accessible, particularly for older adults and individuals with chronic conditions who rely on Medicare Part D coverage.

• Drug Manufacturers: The bill would place new constraints on the pricing of certain high-cost drugs, potentially impacting the revenue and profit margins of pharmaceutical companies.

• Federal Government: The bill's enforcement mechanisms and rebate requirements could generate cost savings for the Medicare program and federal healthcare spending.

Timeline and Next Steps

The Prescription Drug Price Relief Act of 2025 was introduced in the House of Representatives on May 21, 2025. It has been referred to the House Committee on Energy and Commerce for further consideration. If passed by the House, the bill would then need to be approved by the Senate and signed into law by the President to take effect.